Skip to main navigation Skip to search Skip to main content

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

  • Noa Biran
  • , Andrew Ip
  • , Jaeil Ahn
  • , Ronaldo C. Go
  • , Shuqi Wang
  • , Shivam Mathura
  • , Brittany A. Sinclaire
  • , Urszula Bednarz
  • , Michael Marafelias
  • , Eric Hansen
  • , David S. Siegel
  • , Andre H. Goy
  • , Andrew L. Pecora
  • , Ihor S. Sawczuk
  • , Lauren S. Koniaris
  • , Micky Simwenyi
  • , Daniel W. Varga
  • , Lisa K. Tank
  • , Aaron A. Stein
  • , Valerie Allusson
  • George S. Lin, William F. Oser, Roman A. Tuma, Joseph Reichman, Louis Brusco, Kim L. Carpenter, Eric J. Costanzo, Vincent Vivona, Stuart L. Goldberg
  • Georgetown University
  • HACKENSACK UNIVERSITY MEDICAL CENTER
  • COTA
  • John Theurer Cancer Center
  • Palisades Medical Center
  • Hackensack Meridian Health Mountainside Medical Center
  • Pascack Valley Medical Center
  • Solaris Health System
  • Bayshore Medical Center
  • Riverview Medical Center
  • Hackensack Meridian Health
  • Jersey Shore University Medical Center
  • Brick Township
  • Division of Outcomes and Value Research

Research output: Contribution to journal › Article › peer-review

230 Scopus citations

Abstract

Background: Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related mortality among patients requiring intensive care unit (ICU) support for COVID-19. Methods: We did a retrospective observational cohort study at 13 hospitals within the Hackensack Meridian Health network (NJ, USA). We included patients (aged ≥18 years) with laboratory-confirmed COVID-19 who needed support in the ICU. We obtained data from a prospective observational database and compared outcomes in patients who received tocilizumab with those who did not. We applied a multivariable Cox model with propensity score matching to reduce confounding effects. The primary endpoint was hospital-related mortality. The prospective observational database is registered on ClinicalTrials.gov, NCT04347993. Findings: Between March 1 and April 22, 2020, 764 patients with COVID-19 required support in the ICU, of whom 210 (27%) received tocilizumab. Factors associated with receiving tocilizumab were patients' age, gender, renal function, and treatment location. 630 patients were included in the propensity score-matched population, of whom 210 received tocilizumab and 420 did not receive tocilizumab. 358 (57%) of 630 patients died, 102 (49%) who received tocilizumab and 256 (61%) who did not receive tocilizumab. Overall median survival from time of admission was not reached (95% CI 23 days–not reached) among patients receiving tocilizumab and was 19 days (16–26) for those who did not receive tocilizumab (hazard ratio [HR] 0·71, 95% CI 0·56–0·89; p=0·0027). In the primary multivariable Cox regression analysis with propensity matching, an association was noted between receiving tocilizumab and decreased hospital-related mortality (HR 0·64, 95% CI 0·47–0·87; p=0·0040). Similar associations with tocilizumab were noted among subgroups requiring mechanical ventilatory support and with baseline C-reactive protein of 15 mg/dL or higher. Interpretation: In this observational study, patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomised controlled trials are awaited. Funding: None.

Original languageEnglish
Pages (from-to)e603-e612
JournalThe Lancet Rheumatology
Volume2
Issue number10
DOIs
StatePublished - Oct 2020

Fingerprint

Dive into the research topics of 'Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study'. Together they form a unique fingerprint.

Cite this